BOSTON SCIENTIFIC CORP BSX

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients' quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high-performance solutions to address unmet patient needs and reduce the cost of health care. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Last close 45.69 2026-10-23
Market cap $66.22B 2026-06-30 share count
52-week range 41.38 - 105.65

Valuation FY2025 figures against the last close

P/S3.3x
P/E23.6x
P/FCF18.1x
EV/EBITDA13.0x
Dividend yield—
Diluted EPS1.94

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $20.07B$16.75B$14.24B$12.68B$11.89B$9.91B$10.73B$9.82B$9.05B$8.39B
Cost of revenue $6.22B$5.26B$4.34B$3.96B$3.71B$3.46B$3.12B$2.81B$2.59B$2.42B
Gross profit $13.85B$11.49B$9.90B$8.73B$8.18B$6.45B$7.62B$7.01B$6.46B$5.96B
SG&A $6.89B$5.98B$5.19B$4.52B$4.36B$3.79B$3.94B$3.57B$3.29B$3.10B
Total operating expenses $10.24B$8.89B$7.55B$7.08B$6.98B$6.53B$6.10B$5.50B$5.17B$5.51B
Operating income $3.61B$2.60B$2.34B$1.65B$1.20B-$80.0M$1.52B$1.51B$1.28B$447.0M
Interest expense $349.0M$305.0M$265.0M$470.0M$341.0M$361.0M$473.0M$241.0M$229.0M$233.0M
Pre-tax income $3.38B$2.28B$1.99B$1.14B$1.08B-$79.0M$687.0M$1.42B$933.0M$177.0M
Income tax $493.0M$436.0M$393.0M$443.0M$36.0M$2.0M$4.01B$249.0M$828.0M$170.0M
Net income $2.89B$1.85B$1.59B$698.0M$1.04B-$82.0M$4.70B$1.67B$104.0M$347.0M
EPS, basic 1.961.261.080.450.69-0.083.381.210.080.26
EPS, diluted 1.941.251.070.450.69-0.083.331.190.080.25
Shares, diluted (wtd. avg.) 1.49B1.49B1.46B1.44B1.43B1.42B1.41B1.40B1.39B1.38B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.97B$414.0M$865.0M$1.13B$2.17B$2.00B$607.0M$829.0M$1.02B$487.0M
Inventory $2.94B$2.81B$2.48B$1.87B$1.61B$1.35B$1.58B$1.17B$1.08B$955.0M
Total current assets $8.79B$6.92B$6.51B$5.76B$6.32B$6.69B$4.70B$4.00B$3.82B$3.24B
Property, plant and equipment $4.04B$3.29B$2.86B$2.45B$2.25B$2.08B$2.08B$1.78B$1.70B$1.63B
Goodwill $18.28B$17.09B$14.39B$12.92B$11.99B$9.95B$10.18B$7.91B$7.00B$6.68B
Other intangibles $7.02B$6.68B$6.00B$5.90B$6.12B$5.92B$7.89B$6.37B$5.84B$5.88B
Total assets $43.67B$39.40B$35.14B$32.47B$32.23B$30.78B$30.57B$21.00B$19.04B$18.10B
Accounts payable $1.14B$960.0M$942.0M$862.0M$794.0M$513.0M$542.0M$349.0M$530.0M$447.0M
Short-term debt $299.0M$1.78B$531.0M$20.0M$261.0M$13.0M$1.42B$2.25B$1.80B$64.0M
Total current liabilities $5.44B$6.40B$4.93B$3.80B$4.27B$3.68B$4.87B$5.26B$5.65B$3.59B
Long-term debt ————————$3.81B$5.42B
Retained earnings $5.57B$2.67B$819.0M-$750.0M-$1.39B-$2.38B-$2.25B-$6.95B-$8.39B-$8.58B
Total equity $24.23B$21.77B$19.53B$17.57B$16.62B$15.33B$13.88B$8.73B$7.01B$6.73B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $4.53B$3.44B$2.50B$1.53B$1.87B$1.51B$1.84B$310.0M$1.43B$1.18B
Depreciation and amortisation $1.37B$1.27B$1.20B$1.14B$1.09B$1.12B$1.01B$894.0M$844.0M$815.0M
Stock-based compensation $299.0M$266.0M$233.0M$220.0M$194.0M$170.0M$157.0M$140.0M$127.0M$116.0M
Capital expenditure $876.0M$790.0M$711.0M$588.0M$554.0M$376.0M$461.0M$316.0M$319.0M$376.0M
Investing cash flow -$2.64B-$5.69B-$2.57B-$2.01B-$1.60B-$411.0M-$5.04B-$1.92B-$1.01B-$887.0M
Financing cash flow -$395.0M$1.81B$5.0M-$548.0M-$95.0M$293.0M$2.97B$1.43B$110.0M-$206.0M
Dividends paid —$0$28.0M$55.0M$55.0M$28.0M$0$0——
Buybacks ———$0$0$535.0M$0$0—$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000885725-26-000010.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10B 0 10B 20B 30B Revenue, FY2016: 8.4B Gross profit, FY2016: 6B Net income, FY2016: 347M Revenue, FY2017: 9B Gross profit, FY2017: 6.5B Net income, FY2017: 104M Revenue, FY2018: 9.8B Gross profit, FY2018: 7B Net income, FY2018: 1.7B Revenue, FY2019: 10.7B Gross profit, FY2019: 7.6B Net income, FY2019: 4.7B Revenue, FY2020: 9.9B Gross profit, FY2020: 6.4B Net income, FY2020: -82M Revenue, FY2021: 11.9B Gross profit, FY2021: 8.2B Net income, FY2021: 1B Revenue, FY2022: 12.7B Gross profit, FY2022: 8.7B Net income, FY2022: 698M Revenue, FY2023: 14.2B Gross profit, FY2023: 9.9B Net income, FY2023: 1.6B Revenue, FY2024: 16.7B Gross profit, FY2024: 11.5B Net income, FY2024: 1.8B Revenue, FY2025: 20.1B Gross profit, FY2025: 13.9B Net income, FY2025: 2.9B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $8.39B $9.05B $9.82B $10.73B $9.91B $11.89B $12.68B $14.24B $16.75B $20.07B
Gross profit $5.96B $6.46B $7.01B $7.62B $6.45B $8.18B $8.73B $9.90B $11.49B $13.85B
Net income $347.0M $104.0M $1.67B $4.70B -$82.0M $1.04B $698.0M $1.59B $1.85B $2.89B

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
  • Other event Item 8.01
  • Other event Item 8.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%
SOLV Solventum Corp $14.54B 9.6x 0.9%